Shares of Nuwellis, Inc. (NUWE) are surging about 133 percent on Thursday morning after Frontiers in Pediatrics accepted publication of a new single-center retrospective study evaluating Epoprostenol as an alternative anticoagulant for its Aquadex ultrafiltration therapy in critically ill children.
The company's shares are currently trading at $4.40 on the Naasdaq, up 133.33 percent. The stock opened at $5.14 and has climbed as high as $6.3999 so far in today's session. Over the past year, it has traded in a range of $1.83 to $378.35.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.